Prescriptions for ketamine to treat chronic pain have surged by more than 500 percent over the past five years. Despite this dramatic increase, a recent comprehensive review has found insufficient evidence to support its effectiveness for long-term pain relief. The review also raises concerns about potential serious side effects, including delusions and paranoia.
The study, led by Michael Ferraro, a doctoral candidate at the University of New South Wales (UNSW) and Neuroscience Research Australia (NeuRA), urges healthcare providers to engage in open discussions with patients regarding the uncertain benefits of ketamine and the risks of distressing side effects. “We would encourage clinicians to have frank discussions with their patients about the uncertain benefits and potential for distressing side effects,” Ferraro stated, as reported by The Epoch Times.
The rise in ketamine prescriptions coincides with a growing search for alternatives to opioids for managing chronic pain. Traditionally known as an anesthetic used for medical procedures and short-term pain relief, ketamine is increasingly being administered “off-label,” which means it is prescribed for conditions beyond its approved uses, including chronic pain and depression.
Questioning the Efficacy of Ketamine
According to the review, which synthesizes findings from various studies, there is a lack of robust clinical evidence demonstrating that ketamine is an effective long-term solution for chronic pain relief. The researchers emphasize that while some patients may experience temporary benefits, the long-term outcomes remain unclear and warrant caution.
Furthermore, the review highlights the types of side effects that can accompany ketamine use, which may deter patients from continuing this treatment. Patients have reported experiencing hallucinations, mood swings, and cognitive disturbances, raising alarms about the drug’s safety profile when used for prolonged periods.
Healthcare Landscape and Patient Safety
With the opioid crisis prompting healthcare providers to seek alternative therapies, the swift increase in ketamine prescriptions raises important questions about patient safety and informed consent. The review advocates for a balanced approach, stressing that while ketamine may offer some relief for select individuals, the absence of solid evidence supporting its long-term use should not be overlooked.
Healthcare professionals are encouraged to assess each patient’s individual needs and circumstances before considering ketamine as a treatment option. The review underscores the necessity of maintaining an ongoing dialogue about potential risks and benefits, allowing patients to make informed decisions regarding their pain management strategies.
As the landscape of chronic pain treatment continues to evolve, it is crucial for both clinicians and patients to remain vigilant. The findings of this review serve as a reminder that emerging therapies must be rigorously evaluated to ensure their safety and efficacy in the long term.